BioNTech und Pfizer schließen erste Dosierungs-Kohorte der Phase-1/2-Studie mit COVID-19-Impfstoffkandidaten in Deutschland ab
29 avr. 2020 03h42 HE
|
BioNTech SE
MAINZ, Deutschland und NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, „BioNTech” oder „das Unternehmen“), und Pfizer Inc. (NYSE: PFE) haben bekannt gegeben, dass die erste...
BioNTech and Pfizer announce completion of dosing for first cohort of Phase 1/2 trial of COVID-19 vaccine candidates in Germany
29 avr. 2020 03h42 HE
|
BioNTech SE
MAINZ, Germany and NEW YORK, April 29, 2020 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) and Pfizer Inc. (NYSE: PFE) have announced that the first cohort of BioNTech’s...
Possible Connection of MMR Vaccine to Mild COVID-19 Cases Studied by Dr. Larry P. Tilley, World Organization Advisory Board Member
28 avr. 2020 07h51 HE
|
World Organization
ATLANTA, April 28, 2020 (GLOBE NEWSWIRE) -- World Organization Advisory Board Member Dr. Larry Tilley is investigating a possible link between MMR vaccines and COVID-19. Tilley’s investigation began...
Innovation Pharmaceuticals Informed Next Phase of Brilacidin Coronavirus (COVID-19) Testing to Begin Week of May 4
27 avr. 2020 09h30 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 27, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has been...
Emergent BioSolutions Signs Agreement to be U.S. Manufacturing Partner for Johnson & Johnson’s Lead Vaccine Candidate for COVID-19
23 avr. 2020 18h51 HE
|
Emergent BioSolutions
Emergent will provide contract development and manufacturing services to support Johnson & Johnson’s commitment of one billion doses of vaccine for worldwide emergency pandemic useAgreement valued...
BioNTech und Pfizer geben Genehmigung des Paul-Ehrlich-Instituts für erste klinische Studie von COVID-19-Impfstoffkandidaten bekannt
22 avr. 2020 05h00 HE
|
BioNTech SE
Beginn der ersten klinischen Studie für einen COVID-19-Impfstoff in DeutschlandDosisfindung in der Eskalationsphase im Bereich von 1µg bis 100µg Impfstoffherstellung für klinische Studien in BioNTechs...
BioNTech and Pfizer announce regulatory approval from German authority Paul-Ehrlich-Institut to commence first clinical trial of COVID-19 vaccine candidates
22 avr. 2020 05h00 HE
|
BioNTech SE
First COVID-19-related clinical trial to start in GermanyInitial dose escalation phase to target dose range of 1µg to 100µg Clinical supply from BioNTech’s GMP-certified mRNA production facilities in...
Screening of 11,552 Compounds Identifies Innovation Pharmaceuticals’ Brilacidin as One of the Most Promising Potential Inhibitors of the Novel Coronavirus COVID-19
20 avr. 2020 09h00 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., April 20, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, is pleased to report that based on molecular...
Bizagi Launches CoronaPass to Support COVID-19 Anti-Body Testing Certification
15 avr. 2020 08h00 HE
|
Bizagi
NEW YORK, April 15, 2020 (GLOBE NEWSWIRE) -- CoronaPass™, a digital solution launched today to help protect the lives and livelihoods of communities, offers governments, healthcare organizations and...
7 Hills Pharma Announces Coronavirus Vaccine Program Targeting At-Risk Elderly
15 avr. 2020 08h00 HE
|
7 Hills Pharma
HOUSTON, April 15, 2020 (GLOBE NEWSWIRE) -- 7 Hills Pharma, a clinical stage immunotherapy company focused on development of drugs for the treatment and prevention of cancer and infectious diseases,...